hrp0084p3-584 | Adrenals | ESPE2015

CYP11B1 Gene Mutations in Patients with Congenital Adrenal Hyperplasia in Turkey

Bas Firdevs , Ergun-Longmire Berrin , Saka Nurcin , Toksoy Guven , Uyguner Oya , Poyrazoglu Sukran , Ahmed Shaun , Cobb Edward , Altunoglu Umut , Bundak Ruveyde , Darendeliler Feyza , Gunoz Hulya , New Maria I , Wilson Robert

Background: Congenital adrenal hyperplasia (CAH) due to 11β-hydroxylase deficiency (11OHD), a rare autosomal recessive disorder, is the second most common form of CAH, resulting in glucocorticoid deficiency, hyperandrogenism and hypertension.Objective and hypotheses: To investigate the specific CAH mutations in CYP11B1 gene and to examine for genotype-phenotype correlations.Method: 21 patients (n=9, 46, XX; <...

hrp0094ha1 | A Global Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 36-Month Outcomes in Participants Aged &lt;25 Years | ESPE2021

A Global Natural History Study of Fibrodysplasia Ossificans Progressiva (FOP): 36-Month Outcomes in Participants Aged <25 Years

Pignolo Robert J. , Baujat Genevieve , Brown Matthew A. , De Cunto Carmen L. , Hsiao Edward C. , Keen Richard , Al Mukaddam Mona , Le Quan Sang Kim-Hanh , Marino Rose , Houchard Aude , Kaplan Frederick S. ,

Background: FOP is an ultra-rare, severely disabling genetic disorder characterised by progressive heterotopic ossification (HO) following flare-ups. The median age at diagnosis is 5 years, and patients are managed by multiple specialties. No study to date has provided a longitudinal evaluation of FOP. Final data are presented for participants, aged <25 years, enrolled in the first 36-month, prospective, global natural history study of FOP (NCT02322255).</...

hrp0094fc10.5 | Thyroid | ESPE2021

Adjuvant Rituximab – exploratory trial in young people with Graves’ disease

Cheetham Tim , Cole Michael , Abinun Mario , Alalhabadia Amit , Barratt Tim , Kirk Jeremy , Davies Justin , Dimitri Paul , Drake Amanda , Murray Robert , Steele Caroline , Zammitt Nicola , Carnell Sonya , Howell Denise , Prichard Jonathan , Watson Gillian , Matthews John , Pearce Simon ,

Objective: Remission rates in young people with Graves’ hyperthyroidism are 25% or less after a 2-yr course of thionamide antithyroid drug (ATD). Immunomodulatory agents could potentially improve outcome by facilitating immune tolerance. We wanted to explore whether rituximab, a B lymphocyte depleting agent, would increase remission rates when administered with a short course of ATD.Design: This was an investigator-...

hrp0094p1-146 | Sex Endocrinology and Gonads B | ESPE2021

Reaching a definitive diagnosis of hypogonadotropic hypogonadism – experience of a multidisciplinary diagnostic service

Patjamontri Supitcha , Alimussina Malika , Diver Louise A , McMillan Martin , McNeilly Jane D , K Lucas-Herald Angela , Freel Marie , Jones Greg , Kernohan Andrew , Lindsay Robert , McGowan Neil , Perry Colin , Sastry Aparna , Shaikh M Guftar , Tobias Edward S , McGowan Ruth , Ahmed S Faisal ,

Introduction: Hypogonadotropic hypogonadism (HH) is a rare condition, where a definitive diagnosis is often hard to reach.Objectives: To describe the clinical, biochemical and genetic findings in cases with suspected HH in the West of Scotland who were referred for genetic analysis between 2016 and 2020.Methods: Information was collected on clinical assessment including family hist...

hrp0082p1-d2-118 | Fat Metabolism &amp; Obesity (1) | ESPE2014

Plasminogen Activator Inhibitor-1(Pai-1) Levels, Pai-1 Gene Polymorphism, and Family History of Cardiovascular Disease in Relation to Metabolic Parameters in a Sample of Obese Children

Karabouta Zacharoula , Makedou Areti , Argiriou Anagnostis , Papandreou Dimitrios , Xanthopoulou Eleni , Bisbinas Vasiliki , Athanassiadou-Piperopoulou Fani , Rousso Israel

Background: Obesity is a metabolic disorder associated with increased PAI-1 levels in the circulation. This increase is related to insulin resistance and cardiovascular disease (CVD). In adults the relationship between plasma PAI-1 levels and the 4G/5G gene polymorphism in the PAI-1 gene has been demonstrated, but few data exist in children.Objective and hypotheses: To assess the relationship between PAI-1 plasma levels and the PAI-1 4G allele gene polym...

hrp0095p1-228 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Effect of burosumab treatment on phosphate metabolism and bone health in patients with X-linked hypophosphatemic rickets (XLH). Preliminary data within an Italian sample.

Baroncelli Giampiero , Comberiati Pasquale , Rita Sessa Maria , Pelosini Caterina , Grandone Anna , Camodeca Rosanna , Emma Francesco

XLH is the commonest inherited form of rickets. Impaired regulation of fibroblast growth factor 23 (FGF23) due to PHEX gene mutation leads to reduced tubular reabsorption of phosphate (TmP/GFR) and 1,25-dihydroxyvitamin D (1,25(OH)2D) synthesis with hypophosphatemia. Patients show rickets and osteomalacia, bone and muscular pain, stunted growth, and reduced quality of life. We report preliminary data on burosumab therapy in a selected sample of Italian patients.<p class="a...

hrp0089p3-p157 | Fat, Metabolism and Obesity P3 | ESPE2018

A Not So ‘Simple Obesity’

Poluzzi Silvia , Madeo Simona Filomena , Rossi Gloria , Bruzzi Patrizia , Stanghellini Ilaria , Calabrese Olga , Iughetti Lorenzo

Childhood obesity is the consequence of a complex interaction among several factors: environment, genetics, endocrine disorders, medications and other conditions. Genetic factors are described to be causal factors in up to 30–50% of overweight conditions. Although polygenetic obesity is by far the most commonly observed, several obesity related syndromes associated with single gene defects have been identified.Case presentation: A three year old gir...

hrp0094fc9.2 | Growth Hormone and IGFs | ESPE2021

A simple model with height and age at start of treatment with recombinant human growth hormone can accurately predict future growth in children with growth disorders

van Dommelen Paula , Arnaud Lilian , Masne Quentin Le , Koledova Ekaterina ,

Background: A growth prediction model would not only allow patients with growth disorders the opportunity to see the expected effect of their recombinant human growth hormone (r hGH) treatment, but also support healthcare professionals to individualise treatment to optimise growth outcomes.Aim: To develop a growth prediction model in children with growth disorders.Patients and Methods: Height and c...

hrp0082wg8.5 | GPED | ESPE2014

Congenital Hypothyroidism Screening Program: the Costa Rican Experience

Bogarin Roberto

Background: The term congenital hypothyroidism was introduced more than 60 years ago when Radwin et al. first described children with hypothyroid-associated features of severe intellectual disability and growth retardation. It is the most common endocrine congenital disorder and preventable cause of mental retardation. Newborn screening programs are an efficient tool for the secondary prevention of mental retardation associated with untreated congenital hypothyroidism...

hrp0089p2-p293 | Multisystem Endocrine Disorders P2 | ESPE2018

What is the Impact of a Structured Healthcare Pathway Dedicated to Patients in Transition on Their Long-term Follow-up?

Menesguen Florence , Tejedor Isabelle , Malivoir Sabine , Faucher Pauline , Halbron Marine , Popelier Marc , Leger Juliane , Netchine Irene , Polak Michel , Bruckert Eric , Poitou Christine , Touraine Philippe

Management of patients presenting a chronic endocrine or metabolic disease during transition period is a challenge for multiple reasons. The department of Adult Endocrinology and Reproductive Medicine in Pitie Salpêtrière Hospital, Paris has been involved in the management of such patients for many years. However, in our own experience, 81% of patients are still followed-up after 1 year, 71% after 3 years and only 49% after 5 years. Based on such experience, we decid...